BCDA — BioCardia, Inc.

BioCardia (BCDA) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Expenses: Decreased by $460,000 to $2.3 million compared to Q1 2025.
  • R&D Expenses: Fell by $295,000 to $1.2 million, attributed to the closeout of the CardiAMP Heart Failure trial.
  • SG&A Expenses: Decreased to $1.0 million from $1.2 million, mainly due to lower professional service fees.
• Net Loss: Reported at $2.3 million, down from $2.7 million in Q1 2025.
• Net Cash Used in Operations: Slightly increased to $1.7 million from $1.6 million year-over-year.
• Cash Position: Ended the quarter with $951,000 in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• CardiAMP Cell Therapy: Significant progress with FDA breakthrough designation and Medicare reimbursement set at $20,000 per treatment.
• Clinical Data: Positive blinded echocardiography results from the CardiAMP Heart Failure trial, indicating enhanced heart function and reduced negative remodeling in treated patients.
• Regulatory Engagements:
  • Japan's PMDA is inclined to accept the trial data for regulatory submission, with a formal Shonin application expected within 7 months.
  • Completed a Q-Sub meeting with the FDA, which expressed interest in the efficacy results and encouraged completion of the ongoing CardiAMP Heart Failure II trial.
• Upcoming Presentations: Results from the CardiAMP Cell Therapy in chronic myocardial ischemia are set for presentation at the EuroPCR meeting.

3. Forward Guidance and Outlook

• Funding Initiatives: Plans to complete transactions to fund the Japan PMDA submission and the CardiAMP Heart Failure II trial.
• Market Opportunity in Japan: Initial target market of approximately 20,000 patients, with a potential market size of around $400 million based on U.S. reimbursement rates.

4. Bad News, Challenges, or Points of Concern

• Cash Position: The company ended the quarter with a relatively low cash balance of $951,000, raising concerns about capital management and funding for ongoing initiatives.
• Regulatory Process Complexity: The submission process in Japan involves extensive auditing and documentation, which could pose delays or complications.
• Market Penetration: Initial market size is limited, and the company may face challenges in expanding its reach beyond the initial 20,000 patients.

5. Notable Q&A Insights

• Regulatory Process in Japan: The submission will require thorough auditing of clinical data and manufacturing processes, with an expected review timeline of about one year post-submission.
• Market Integration: CardiAMP is expected to address a significant unmet need in Japan, with potential integration into existing treatment regimens for ischemic heart failure.
• Reimbursement Expectations: While the reimbursement in Japan may not match U.S. levels, the therapy's cost-effectiveness is highlighted as a competitive advantage.

Overall, BioCardia is making strides in its clinical and regulatory efforts for CardiAMP Cell Therapy, but faces challenges related to cash management and the complexities of the regulatory landscape.